We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

subscriber-only content

LOG-IN

SUBSCRIBE NOW

for more website access

The content of this section is only available to Investors Chronicle online subscribers.

Consort Medical looking defensive

These full-year figures from Consort Medical suggest that the long integration process that followed 2005's acquisition of medical devices unit King Systems is nearing an end. For example, exceptional items - which have long affected the income statement - fell from £4.7m to £1.6m. And, despite worries over eurozone exposure, new product launches and organic inhaler sales growth helped reiterate Consort's defensive qualities - leaving the shares looking attractive.

subscriber-only content

LOG-IN

SUBSCRIBE NOW

visible-status-Subscription-Only story-url-Consort Medical prelims 2012 14 June 2012.xml

By Julian Hofmann,
15 June 2012

Print this article Share this article